BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x March 31, 2010

[FORM 10-Q (Mark One) x March 31, 2010 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [ASSETS ACQUISITION AGREEMENT Party A: Shaanxi Biostar Biotech, Ltd. Legal Representative: WANG Ronghua Party B: Xi’an Meipude Bio-Technology Co., Ltd. Legal Representative: SUN Yaomei On March 28, 2010, Party A and Party B again entered into the following agreement concerning Party A’s acquisition of Party B’s assets. A. Party B agrees to transfer all of the technologies and assets of] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]

By | 2016-03-03T14:29:02+00:00 May 14th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2010 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [ASSETS ACQUISITIONREEMENT Party A:Shaanxi Biostar Biotech, Legal Representative:WANG Ronghua Party B: Xian Meipude Bio-Technology Legal Representative:SUN Yaomei On March 28, 2010, Party A and Party Bain entered into the followingreementncerning Party acquisition of Party Bssets. A. Party Brees to transferl of the technologies andsets of Xian Meipude Bio-Technology to Party A, and Party Arees to] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 6 EX-32.2]

By | 2016-02-07T17:26:38+00:00 May 14th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x March 31, 2010

[FORM 10-Q (Mark One) x March 31, 2010 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [ASSETS ACQUISITIONREEMENT Party A:Shaanxi Biostar Biotech, Legal Representative:WANG Ronghua Party B: Xian Meipude Bio-Technology Legal Representative:SUN Yaomei On March 28, 2010, Party A and Party Bain entered into the followingreementncerning Party acquisition of Party Bssets. A. Party Brees to transferl of the technologies andsets of Xian Meipude Bio-Technology to Party A, and Party Arees to] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 6 EX-32.2]

By | 2016-02-07T17:27:30+00:00 May 14th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET XIANYANG, China, May 12, 2010 (Xinhua-PRNewswire-FirstCall) http://www.viavid.net http://viavid.net/dce.aspx?sid=00007582 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at About Biostar Pharmaceuticals, Inc. Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary]

By | 2016-03-03T14:30:37+00:00 May 12th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010

[Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET XIANYANG, China, May 12, 2010 (Xinhua-PRNewswire-FirstCall) http://www.viavid.net http://viavid.net/dce.aspx?sid=00007582 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at About Biostar Pharmaceuticals, Inc. Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary]

By | 2016-03-03T14:32:29+00:00 May 12th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[SKYSTAR COMMENCES TESTING ON TWO ADDITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THE COMPANY’S PRODUCT LINES The new dosage forms projected to generate $5 million in additional revenue by fiscal 2011 XI'AN, CHINA – May 12, 2010 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms will adhere]

By | 2016-03-01T06:17:05+00:00 May 12th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: SKYSTAR COMMENCES TESTING ON TWO ADDITIONAL NEW PRODUCT

[SKYSTAR COMMENCES TESTING ON TWO ADDITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THE COMPANY’S PRODUCT LINES The new dosage forms projected to generate $5 million in additional revenue by fiscal 2011 XI'AN, CHINA – May 12, 2010 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms will adhere]

By | 2016-03-01T06:17:48+00:00 May 12th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)

[SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THEMPANYS PRODUCT LINES The new dosage forms projected to generate $5 million inditional revenue by fiscal 2011 XI'AN, CHINA May 12, 2010 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms willhere to good manufacturing]

By | 2016-02-05T04:23:55+00:00 May 12th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS

[SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THEMPANYS PRODUCT LINES The new dosage forms projected to generate $5 million inditional revenue by fiscal 2011 XI'AN, CHINA May 12, 2010 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms willhere to good manufacturing]

By | 2016-02-05T04:24:46+00:00 May 12th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, to Host Fiscal Year 2010 First Quarter Earningsnferencell on Monday, May 17, 2010 at 9:30 a.m. ET XIANYANG, China, May 12, 2010 (Xinhua-PRNewswire-FirstCall) http://www.viavid.net http://viavid.net/dce.aspx?sid=00007582 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp Thisll is being webst by ViaVid Broadcasting andn be accessed at ViaVid's website atout Biostar Pharmaceuticals,]

By | 2016-02-07T17:28:10+00:00 May 12th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar